US FDA issues Sun with Form 483 after Dadra plant inspection

By Gareth Macdonald

- Last updated on GMT


Related tags Pharmacology Pharmaceutical drug Food and drug administration

The US FDA has handed Sun Pharmaceutical Industries Ltd a Form 483 detailing critical observations made during an inspection of its Dadra, India facility.

Sun announced the Form 483 in a Bombay Stock Exchange (BSE) filing​ on Saturday, explaining that the Food and Drug Administration (FDA) inspection team which audited the site on April 13 identified 11 issues. Details of the problems were not provided.

The Indian drug manufacturer said it is responding to the letter but declined to comment when contacted by

The plant which opened in 2002​ manufactures active pharmaceutical ingredients​ (APIs) and oral sold drugs – tablets and capsules – for India and international markets. According to Sun’s website the facility has capacity to produce 2400mill tablets a year.


The Form 483 comes months​ after the US FDA told Sun it had more to do to bring its plant in Halol, Gujarat – which also makes finished drug products – up to code.

Sun has been working to address problems at the Halol facility since 2015​ when it was issued with a warning letter by the US FDA.

Sun had expected Halol regain compliance last year.

However, in December​ it announced it had received a new Form 483 after an inspection earlier that month. In February​, the firm said it had submitted its response to the US regulator.

According to Sun, the Halol problems impacted its US revenues in fiscal 2016.

Related news

Show more

Related products

show more

Increasing the Bioavailability of Oncology Drugs

Increasing the Bioavailability of Oncology Drugs

Content provided by Lonza Small Molecules | 13-Nov-2023 | White Paper

Oral tyrosine kinase inhibitors (TKIs) are a class of cancer drugs that can be highly susceptible to issues with solubility in the gastrointestinal tract

Efficient Freezing & Storage of Biopharmaceuticals

Efficient Freezing & Storage of Biopharmaceuticals

Content provided by Single Use Support | 06-Nov-2023 | White Paper

Various options exist for freezing biopharmaceutical bulk material, but selecting the most effective and efficient approach for each cold chain can be...

Manufacturing Drugs with Highly Potent APIs

Manufacturing Drugs with Highly Potent APIs

Content provided by Altasciences | 28-Sep-2023 | White Paper

In this issue of The Altascientist, we examine the critical considerations for the safe and compliant manufacture of drugs with highly potent APIs (HPAPIs),...

Follow us


View more